MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$255K
EPS
$0.01
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
Research and development expenses
73 141
General and administrative expenses
178 174
Operating loss
-251 -315
Total financial expense
-4 -7
Net loss
-255 -322
Basic net loss per share (in dollars per share)
0.01 0.02
Diluted net loss per share (in dollars per share)
0.01 0.02
Weighted average number of shares of common stock used in computing basic net loss per share (in shares)
19,626,418 19,626,418
Weighted average number of shares of common stock used in computing diluted net loss per share (in shares)
19,626,418 19,626,418
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$255K Total financialexpense-$4K Operating loss-$251K General andadministrative expenses$178K Research and developmentexpenses$73K

Raphael Pharmaceutical Inc. (RAPH)

Raphael Pharmaceutical Inc. (RAPH)